HHS Drug Testing Panel Guidelines

Content

ACTION:

Issuance of authorized drug testing panels.

SUMMARY:

HHS herein publishes the panels of Schedule I and II drugs and biomarkers authorized for testing in federal workplace drug
testing programs. The Department has made no revisions to the current drug testing panels for both urine and oral fluid and
current required nomenclature for laboratory and Medical Review Officer Reports, effective July 7, 2025.

DATES:

The current authorized drug testing panels and required report nomenclature remain in effect.

FOR FURTHER INFORMATION CONTACT:

Eugene D. Hayes, Ph.D., MBA, SAMHSA, Center for Substance Abuse Prevention, Division of Workplace Programs; 5600 Fishers Lane,
Room 16N02, Rockville, MD 20857, by telephone (240) 276-1459 or by email at Eugene.Hayes@samhsa.hhs.gov.

SUPPLEMENTARY INFORMATION:

The drug testing panels in this notification specify the analytes and cutoffs for federal agency workplace drug testing specimens
and the nomenclature (i.e., analyte names and abbreviations) that

must be used to report federal workplace drug test results. There are no changes to the drug testing analytes, test cutoffs,
and report nomenclature published in the January 16, 2025, Notification (90 FR 4662). The Department has edited footnotes
1 and 2 in the drug testing panels for clarity and correctness.

This notification is in accordance with Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs
using Urine (UrMG, 88 FR 70768) and the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid
(OFMG, 88 FR 70814). Section 3.4 of Subpart C calls upon the Secretary of HHS to “publish the drug and biomarker test analytes
and cutoffs (i.e., the drug testing panel' andbiomarker testing panel') for initial and confirmatory drug and biomarker tests in the
Federal Register
each year,” and make them available on the internet at http://www.samhsa.gov/workplace. Section 3.4 of the UrMG and the OFMG also requires HHS-certified laboratories, instrumented initial test facilities (IITF,
urine only), and Medical Review Officers to use the nomenclature (i.e., analyte names and abbreviations) published with the drug and biomarker testing panels to report federal workplace drug test
results.

Costs and Benefits

No analysis is needed because the current drug testing panels and nomenclature tables remain in effect. Currently, the Department
does not require HHS-certified test facilities to implement authorized biomarker tests. Each laboratory and IITF should conduct
their own cost analysis when deciding whether to offer biomarker testing to federally regulated clients. The Department will
consider costs when deciding whether to require all certified test facilities to test for a specific biomarker.

| Urine | |
| --- | |
| Abbreviation | Analyte |
| Δ9THCC | Δ-9-tetrahydrocannabinol-9-carboxylic acid. |
| BZE | Benzoylecgonine. |
| COD | Codeine. |
| MOR | Morphine. |
| HYC | Hydrocodone. |
| HYM | Hydromorphone. |
| OXYC | Oxycodone. |
| OXYM | Oxymorphone. |
| 6-AM | 6-Acetylmorphine. |
| PCP | Phencyclidine. |
| FENT | Fentanyl. |
| NFENT | Norfentanyl. |
| AMP | Amphetamine. |
| MAMP | Methamphetamine. |
| MDMA | Methylenedioxymethamphetamine. |
| MDA | Methylenedioxyamphetamine. |

| HHS Drug Testing Panel—Urine | | | |
| --- | | | |
| Initial test analyte | Initial test

           cutoff 1 (ng/mL) | Confirmatory test analyte | Confirmatory test cutoff 
           (ng/mL) |

| Marijuana metabolite (Δ9THCC) | 2 50 | Δ9THCC | 15 |
| Cocaine metabolite (Benzoylecgonine) | 2 150 | Benzoylecgonine | 100 |
| Codeine/Morphine | 2,000 | Codeine | 2,000 |
| | | Morphine | 4,000 |
| Hydrocodone/Hydromorphone | 300 | Hydrocodone | 100 |
| | | Hydromorphone | 100 |
| Oxycodone/Oxymorphone | 100 | Oxycodone | 100 |
| | | Oxymorphone | 100 |
| 6-Acetylmorphine | 10 | 6-Acetylmorphine | 10 |
| Phencyclidine | 25 | Phencyclidine | 25 |
| Fentanyl 3 | 1 | Fentanyl | 1 |
| | | Norfentanyl | 1 |
| Amphetamine/Methamphetamine | 500 | Amphetamine | 250 |
| | | Methamphetamine | 250 |
| MDMA/MDA | 500 | Methylenedioxymethamphetamine | 250 |
| | | Methylenedioxyamphetamine | 250 |
| 1 For grouped analytes (i.e., two or more analytes that are in the same drug class and have the same initial test cutoff): | | | |
| Immunoassay: The test must be calibrated with one analyte from the group identified as the target analyte. The cross-reactivity of the
immunoassay to the other analyte(s) within the group must be 80 percent or greater; if not, separate immunoassays must be
used for the analytes within the group. | | | |
| Alternate technology: Either one analyte or all analytes from the group must be used for calibration, depending on the technology. For a technology
that measures a response from the entire group without differentiating between analytes (e.g., an activity-based assay), the laboratory must compare the result to the initial test cutoff. In the case of an alternate technology
that differentiates and quantifies each analyte in the group, the laboratory must compare each analyte's result to the confirmatory
test cutoff and reflex specimens with a positive initial test result to confirmatory testing. | | | |
| 2 Alternate technology: When an alternate technology initial test is specific for the target analyte, the confirmatory test cutoff must be used for
the initial test (i.e., Δ9THCC, 15 ng/mL; BZE, 100 ng/mL). | | | |
| 3 A fentanyl immunoassay must have at least 5% cross-reactivity to norfentanyl. | | | |

HHS Biomarker Testing Panel—Urine

SAMHSA has not yet authorized routine testing for any biomarker in urine. HHS-certified laboratories and IITFs may request
authorization to test federal agency specimens for a biomarker upon Medical Review Officer request by submitting supporting
documentation and assay validation records to the National Laboratory Certification Program for SAMHSA review and approval.

| Oral fluid | |
| --- | |
| Abbreviation | Analyte |
| Δ9THC | Δ-9-tetrahydrocannabinol. |
| COC | Cocaine. |
| BZE | Benzoylecgonine. |
| COD | Codeine. |
| MOR | Morphine. |
| HYC | Hydrocodone. |
| HYM | Hydromorphone. |
| OXYC | Oxycodone. |
| OXYM | Oxymorphone. |
| 6-AM | 6-Acetylmorphine. |
| PCP | Phencyclidine. |
| FENT | Fentanyl. |
| AMP | Amphetamine. |
| MAMP | Methamphetamine. |
| MDMA | Methylenedioxymethamphetamine. |
| MDA | Methylenedioxyamphetamine. |

| HHS drug testing panel—undiluted (neat) oral fluid | | | |
| --- | | | |
| Initial test analyte | Initial test

           cutoff 1 (ng/mL) | Confirmatory test analyte | Confirmatory 
           test cutoff(ng/mL) |

| Marijuana (Δ9THC) | 2 4 | Δ9THC | 2 |
| Cocaine/Benzoylecgonine | 15 | Cocaine
Benzoylecgonine | 8
8 |
| Codeine/Morphine | 30 | Codeine
Morphine | 15
15 |
| Hydrocodone/Hydromorphone | 30 | Hydrocodone
Hydromorphone | 15
15 |
| Oxycodone/Oxymorphone | 30 | Oxycodone
Oxymorphone | 15
15 |
| 6-Acetylmorphine | 2 4 | 6-Acetylmorphine | 2 |
| Phencyclidine | 10 | Phencyclidine | 10 |
| Fentanyl | 2 4 | Fentanyl | 1 |
| Amphetamine/Methamphetamine | 50 | Amphetamine
Methamphetamine | 25
25 |
| MDMA/MDA | 50 | Methylenedioxymethamphetamine
Methylenedioxyamphetamine | 25
25 |
| 1 For grouped analytes (i.e., two or more analytes that are in the same drug class and have the same initial test cutoff): | | | |
| Immunoassay: The test must be calibrated with one analyte from the group identified as the target analyte. The cross reactivity of the
immunoassay to the other analyte(s) within the group must be 80 percent or greater; if not, separate immunoassays must be
used for the analytes within the group. | | | |
| Alternate technology: Either one analyte or all analytes from the group must be used for calibration, depending on the technology. For a technology
that measures a response from the entire group without differentiating between analytes (e.g., an activity-based assay), the laboratory must compare the result to the initial test cutoff. In the case of an alternate technology
that differentiates and quantifies each analyte in the group, the laboratory must compare each analyte's result to the confirmatory
test cutoff and reflex specimens with a positive initial test result to confirmatory testing. | | | |
| 2 Alternate technology: When an alternate technology initial test is specific for the target analyte, the confirmatory test cutoff must be used for
the initial test (i.e., Δ9THC, 2 ng/mL; 6-AM, 2 ng/mL; FENT, 1 ng/mL). | | | |

HHS Biomarker Testing Panel—Oral Fluid

SAMHSA has not yet authorized routine testing for any biomarker in oral fluid. HHS-certified laboratories may request authorization
to test Federal agency specimens for a biomarker by submitting supporting documentation and assay validation records to the
National Laboratory Certification Program for SAMHSA review and approval. Authorized biomarker test cutoffs for oral fluid
will be based on undiluted (neat) oral fluid.

Robert F. Kennedy, Jr., Secretary, Department of Health and Human Services. [FR Doc. 2026-04981 Filed 3-12-26; 8:45 am] BILLING CODE 4162-20-P

Download File

Download